Intralesional Rituximab for the Treatment of Conjunctival Indolent Lymphoma
Status:
Unknown status
Trial end date:
2015-10-01
Target enrollment:
Participant gender:
Summary
Phase II, monocentric, open label study to assess safety and activity of intralesional
Rituximab for the treatment of indolent CD20+ lymphoma of conjunctiva.